Cellular immunity to Streptococcus pneumoniae: implications for vaccine-mediated prevention [0.03%]
肺炎链球菌的细胞免疫及其在疫苗预防中的作用
Heather VanSeggelen,Daniela M Ferreira,Richard Malley et al.
Heather VanSeggelen et al.
Introduction: Streptococcus pneumoniae asymptomatically colonizes the nasopharynx but can also cause mucosal infections or invasive pneumococcal disease. Despite the significant positive impact of pneumococcal conjugate v...
Perceived implementation determinants of influenza vaccination by Chinese older adults: a CFIR-guided qualitative study comparing Beijing and Guizhou [0.03%]
基于CFIR的定性研究：比较北京和贵州老年人群流感疫苗接种实施确定因素的感知状况
Yuxi Liu,Jiarui Zheng,Rujing Shi et al.
Yuxi Liu et al.
Background: Influenza vaccination is an evidence-based intervention for older adults. However, vaccination coverage remains low and uneven in China, indicating persistent evidence-practice gap. Although older adults often...
Comparative Study
Expert review of vaccines. 2026 Dec;25(1):2708193. DOI:10.1080/14760584.2026.2708193 2026
Modeling the public health impact of vaccination with Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025-2026 formula in the pediatric population aged 5-17 years at high risk of severe outcomes from COVID-19 in the United States [0.03%]
在美国高危5-17岁儿童人群中接种辉瑞-BioNTech COVID-19疫苗(LP.8.1, 2025-2026)对公共卫生产生的影响建模
Alon Yehoshua,Manuela Di Fusco,Abby E Rudolph et al.
Alon Yehoshua et al.
Introduction: This study evaluated the potential public health impact of receiving Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025-2026 formula, in the US pediatric population aged 5-17 years at high risk of severe outcome...
Cost-effectiveness of RSVpreF for the prevention of respiratory syncytial virus illness among high-risk adults in Germany [0.03%]
德国高危成人预防呼吸道合胞病毒疾病的RSVpreF成本效益分析
Erin Quinn,Mary MacKinnon,Severin Freisberg et al.
Erin Quinn et al.
Introduction: Vaccination against lower respiratory tract illness due to respiratory syncytial virus (RSV-LRTI) is approved in Europe for all adults aged ≥18 years. The German Standing Committee on Vaccination (STIKO), h...
Epidemiological characteristics of varicella and factors associated with breakthrough varicella among children aged 0-14 years in Jiangsu Province, China [0.03%]
中国江苏省0～14岁儿童水痘流行特征及疫苗突破感染的影响因素分析
Mei Li,Yan Xu,Yurong Li et al.
Mei Li et al.
Background: This study aimed to explore the epidemiological characteristics of varicella and breakthrough varicella (BV), as well as factors associated with the BV proportion during 2021-2024. ...
Recent advances in the development of a vaccine to target meningococcal serogroup X [0.03%]
奈瑟氏菌X血清群脑膜炎疫苗研发进展recent advances in the development of a vaccine to target meningococcal serogroup x
Kelly Townsend-Payne,Jennifer Louth,Ray Borrow et al.
Kelly Townsend-Payne et al.
Introduction: Serogroup X has emerged as an important cause of invasive meningococcal disease across Sub-Saharan Africa. Recent advances in serogroup X vaccines were reviewed. ...
Adapted XBB.1.5 vaccine effectiveness against severe COVID-19 outcomes among immunocompromised persons in 2023-24 in six European countries: a VEBIS-EHR network study [0.03%]
2023-24年欧洲六国免疫功能低下人群中针对严重新冠肺炎结局的XBB.1.5适应性疫苗效力：VEBIS-EHR网络研究
Alexandre Blake,James Humphreys,Kate Olson et al.
Alexandre Blake et al.
Background: We estimated the XBB.1.5 vaccine effectiveness (VE) against COVID-19 hospitalization and death in Belgium, Denmark, Italy, Portugal, Spain (Navarre), and Sweden following the 2023-24 fall vaccination campaign ...
Multicenter Study
Expert review of vaccines. 2026 Dec 31;25(1):2708184. DOI:10.1080/14760584.2026.2708184 2026
When precision medicine meets rigid vaccination: bridging the policy gap for patients on biologics [0.03%]
精准医疗与严格的疫苗接种政策之间的缺口：生物制剂患者的政策差距问题
Dingxian He,Yunlu Zhang,Sushan Luo et al.
Dingxian He et al.
Adult respiratory syncytial virus infection and community-acquired pneumonia: pathogenesis, diagnostic challenges and the clinical implications [0.03%]
呼吸道合胞病毒感染和社区获得性肺炎：发病机制、诊断挑战及临床意义
Seong-Beom Park,Saeyong Lee,Sang-Kyu Shin et al.
Seong-Beom Park et al.
Introduction: Community-acquired pneumonia (CAP) remains a significant cause of adult morbidity and mortality. Respiratory syncytial virus (RSV) contributes meaningfully to adult CAP, particularly in older adults and thos...
Quantifying the societal benefits of adult immunization against respiratory diseases in France: a benefit cost analysis [0.03%]
法国成人呼吸道疾病免疫接种社会效益量化分析：效益成本分析方法
Matthew Napier,Simon Brassel,Ellie Tunnicliffe et al.
Matthew Napier et al.
Background: Pneumococcal disease, respiratory syncytial virus (RSV), influenza, and COVID-19 place a significant burden on France's population health, health system, and economy. Older adults and adults in clinical risk g...